Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Preeclampsia Drugs Market Expected to Be in 2029?

The market size for drugs treating preeclampsia has experienced robust growth in the past few years. The market, which was valued at $1.25 billion in 2024, is projected to increase to $1.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. The notable growth during the historic period is due to a heightened awareness of maternal health, investment in research and development, concerns over neonatal health, and early detection methods.

The market size for preeclampsia drugs is anticipated to experience considerable expansion over the coming years. With a compound annual growth rate (CAGR) of 11.2%, it is estimated to reach “$2.1 billion in 2029. This projected growth through the forecast period is driven by factors such as personalized treatment, non-invasive diagnostic tools, targeted treatment methods, and health equality programs. Other trends expected during the forecast period include preventive tactics, patient-focused care strategies, constant monitoring, and regulatory emphasis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

What Are The Contributors To Demand In The Preeclampsia Drugs Market?

The growth of the preeclampsia drug market is expected to be driven by an increase in diabetes cases among pregnant women. Diabetes, a long-term metabolic disease, is defined by elevated levels of blood glucose or blood sugar. Preeclampsia, a detrimental condition in pregnancy, involves heightened blood pressure and damage to organs. A commonly used drug for preeclampsia is Metformin, especially for pregnant women with early-onset preeclampsia. As an example, the total incidence of gestational diabetes mellitus (GDM) rose by 6.56% in 2022 to reach 20,865 cases, according to the National Library of Medicine, a prominent US biomedical library and center for biomedical informatics, in December 2022. As a result, the surge in diabetes cases among pregnant women is projected to fuel the preeclampsia drug market.

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management

What Notable Trends Are Shaping The Direction Of The Preeclampsia Drugs Market?

In an effort to strengthen their standing in the preeclampsia medication market, leading firms are focusing on the development of innovative drug solutions. Comanche Biopharma Corp., a biopharmaceutical company based in the United States, announced in March 2023 that their unique siRNA treatment for preeclampsia, known as CBP-4888, had received approval for an Investigational New Drug (IND) application from the Food and Drug Administration (FDA). CBP-4888, an siRNA therapy, is administered subcutaneously and works by reducing the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The main cause of preeclampsia is the excessive production of sFLT1 protein in the placenta, which then enters the mother’s bloodstream. By treating preeclampsia symptoms such as high blood pressure and organ damage, CBP-4888 may potentially allow for the safe prolonging of pregnancy.

Who Are The Top-Ranked Companies In The Preeclampsia Drugs Market Today?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

How Is Preeclampsia Drugs Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model